Provided by Tiger Fintech (Singapore) Pte. Ltd.

Supernus Pharmaceuticals

32.34
-1.2500-3.72%
Post-market: 32.340.00000.00%16:34 EDT
Volume:690.52K
Turnover:22.58M
Market Cap:1.81B
PE:29.22
High:33.83
Open:33.83
Low:32.20
Close:33.59
Loading ...

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

MT Newswires Live
·
02 Jul

Sage Therapeutics to Cut Most Jobs Following Acquisition by Supernus Pharmaceuticals

MT Newswires Live
·
01 Jul

Supernus Pharmaceuticals Inc. Conducted Annual Stockholders' Meeting

Reuters
·
18 Jun

Supernus Pharmaceuticals (SUPN) Receives a Hold from Cantor Fitzgerald

TIPRANKS
·
17 Jun

H.C. Wainwright sees potential competition for Sage from Biogen

TIPRANKS
·
17 Jun

Top Midday Stories: Equity Markets Rise on Hopes of Containment of Israel-Iran Hostilities; Meta to Introduce Ads on WhatsApp

MT Newswires Live
·
16 Jun

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

MT Newswires Live
·
16 Jun

Supernus Exec Says on Sage Deal: Most of the Synergies Will Be on the General and Administrative Expenses Side and the R&D Side - Conf Call

THOMSON REUTERS
·
16 Jun

Supernus Exec Says Sage's Drug Zurzuvae Has the Potential to Be the Standard of Care in Post Partum Depression - Conf Call

THOMSON REUTERS
·
16 Jun

Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral

MT Newswires Live
·
16 Jun

SAGE Therapeutics Announces Merger with Supernus Pharmaceuticals

TIPRANKS
·
16 Jun

BRIEF-Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio

Reuters
·
16 Jun

Sage Therapeutics Shares Jump 33.4% Premarket After Supernus Pharmaceuticals to Acquire Co for up to $795 Mln

THOMSON REUTERS
·
16 Jun

Supernus Pharmaceuticals to Acquire Sage Therapeutics for $561 Million in Cash Deal

Reuters
·
16 Jun

Supernus Pharmaceuticals Inc - Expected to Be Significantly Accretive in 2026 With Potential Cost Synergies of up to $200 Mln on an Annual Basis

THOMSON REUTERS
·
16 Jun

Supernus Pharmaceuticals Inc - Dealfor an Aggregate of up to Approximately $795 Mln or $12.00 per Share

THOMSON REUTERS
·
16 Jun

Supernus Pharmaceuticals Inc - Upfront Cash Payment of $8.50 per Share

THOMSON REUTERS
·
16 Jun

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio

THOMSON REUTERS
·
16 Jun

Supernus announces Paragraph IV ANDA filings for Qelbree

TIPRANKS
·
29 May

Supernus Pharmaceuticals Inc - to Enforce Intellectual Property Rights for Qelbree - SEC Filing

THOMSON REUTERS
·
29 May